Mesna

Rhabdomyosarcoma

St. Jude Children's Research HospitalSmall moleculePhase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 73/ 100

Competitive context

58 Active assets in the Rhabdomyosarcoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Eisai Inc.	Phase 2	BBB
Ipilimumab Children's National Research Institute	Phase 2	BB
Eloxatin National Cancer Institute (NCI)	Phase 2	BB
Irinotecan Milton S. Hershey Medical Center	Phase 2	BB
CALCIUM PHOSPHATE Children's Oncology Group	Phase 3	BB

View all 50 →

Same molecule, other indications

Mesna is also rated in:

Hodgkin's LymphomaDormant

BB

Indicative ·

69 / 100

disease related to hematopoietic stem cell transplantDormant

BB

Indicative ·

69 / 100

NK/T-cell LymphomaDormant

BB

Indicative ·

67 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.